Outcomes in atrial fibrillation patients with and without left ventricular hypertrophy when treated with a lenient rate-control or rhythm-control strategy

American Journal of Cardiology

Volumn 113, Issue 7, 2014, Pages 1159-1165

  Badheka, Apurva O ^a   Shah, Neeraj ^b   Grover, Peeyush M ^c   Patel, Nileshkumar J ^b   Chothani, Ankit ^d   Mehta, Kathan ^e   Singh, Vikas ^c   Deshmukh, Abhishek ^f   Savani, Ghanshyambhai T ^c   Rathod, Ankit ^g   Panaich, Sidakpal S ^a   Patel, Nilay ^a   Arora, Shilpkumar ^a   Bhalara, Vipulkumar ^a   Coffey, James O ^c   Mitrani, Raul D ^c   Halperin, Jonathan L ^h   Viles Gonzalez, Juan F ^c  

^a DETROIT MEDICAL CENTER   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e DREXEL UNIVERSITY   (United States)

^f UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SOTALOL; WARFARIN;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION FOLLOW UP INVESTIGATION OF RHYTHM MANAGEMENT; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LENIENT RATE CONTROL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITRAL VALVE REGURGITATION; MORBIDITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; RHYTHM CONTROL; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROGNOSIS; SURVIVAL RATE; UNITED STATES;

EID: 84896034659     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.12.021     Document Type: Article

References (28)

1. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825.
2. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509.
3. Patel NJ, Hoosien M, Deshmukh A, Badheka AO, Grover PM, Shah N, Singh V, Mehta K, Chothani A, Savani GT, Arora S, Bhalara V, Patel N, Khalpada D, Rathod A, Vazzana TJ, Lafferty J, Viles-Gonzalez JF, Mitrani RD. Digoxin significantly improves all-cause mortality in atrial fibrillation patients with severely reduced left ventricular systolic function. Int J Cardiol 2013;1689:e84-e86.
4. Mehta K, Grover PM, Shah N, Patel NJ, Chothani A, Singh V, Savani GT, Deshmukh A, Rathod A, Patel N, Panaich SS, Arora S, Nalluri N, Khalpada D, Bhalaria V, Parmar NG, Badheka AO, Viles-Gonzalez JF, Mitrani RD. Non-influence of lipid lowering therapy in atrial fibrillation recurrence. Int J Cardiol 2013;168:5006-5007.
5. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010;123:646-651.
6. Badheka AO, Rathod A, Kizilbash MA, Bhardwaj A, Ali O, Afonso L, Jacob S. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction. Am J Cardiol 2011;108:1283-1288.
7. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S. Impact of lipid-lowering therapy on outcomes in atrial fibrillation. Am J Cardiol 2010;105:1768-1772.
8. Deshmukh A, Pant S, Kumar G, Badheka AO, Paydak H. Impact of obesity on atrial fibrillation hospitalization. Int J Cardiol 2012;159:241-242.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group, American Society of Echocardiography's Guidelines and Standards Committee, European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463. (Pubitemid 41821197)
10. Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovasc Ultrasound 2005;3:17.
11. Cooper HA, Bloomfield DA, Bush DE, Katcher MS, Rawlins M, Sacco JD, Chandler M, AFFIRM Investigators. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol 2004;93:1247-1253. (Pubitemid 38607392)
12. Haider A, Larson M, Benjamin E, Levy D. Increased left ventricular mass and hypertrophy are associated with an increased risk for sudden death. J Am Coll Cardiol 1998;32:1454-1459. (Pubitemid 28522409)
13. Bender SR, Friedman DJ, Markowitz SM, Lerman BB, Okin PM. Electrocardiographic left ventricular hypertrophy predicts arrhythmia and mortality in patients with ischemic cardiomyopathy. J Interv Card Electrophysiol 2012;34:237-245.
14. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992;117:831-836.
15. Zimetbaum PJ, Buxton AE, Batsford W, Fisher JD, Hafley GE, Lee KL, O'Toole MF, Page RL, Reynolds M, Josephson ME. Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation 2004;110:766-769. (Pubitemid 39096001)
16. Ali S, Goodman SG, Yan RT, Budaj A, Fox KA, Gore JM, Brieger D, López-Sendón J, Langer A, van de Werf F, Steg PG, Yan AT. Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes. Am Heart J 2011;161:878-885.
17. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006;296:1242-1248. (Pubitemid 44394895)
18. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010;31:2271-2279.
19. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol 2008;1:337-343.
20. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlöf B, Devereux RB, Okin PM, LIFE Study Investigators. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2004;43:1029-1034. (Pubitemid 38579909)
21. Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990;15:43-51. (Pubitemid 20034248)
22. Marcus ML, Harrison DG, Chilian WM, Koyanagi S, Inou T, Tomanek RJ, Martins JB, Eastham CL, Hiratzka LF. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987;75:I19-I25.
23. Cohen-Solal Alain. Left ventricular diastolic dysfunction: pathophysiology, diagnosis and treatment. Nephrol Dia Transplant 1998;13(suppl 4):3-5.
24. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73.
25. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
26. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566. (Pubitemid 20176696)
27. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000;35:580-586. (Pubitemid 30108152)
28. Fung JW, Sanderson JE, Yip GW, Zhang Q, Yu CM. Impact of atrial fibrillation in heart failure with normal ejection fraction: a clinical and echocardiographic study. J Card Fail 2007;13:649-655. (Pubitemid 47516702)